Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Targeted therapy doubles progression-free survival in rare bile duct cancer

2

Jul 2026

Targeted therapy doubles progression-free survival in rare bile duct cancer

Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy – including a near doubling of progression-free survival compared to expectations with standard of care – in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

ACMG issues guidance for reporting uncertain genetic test variants

1

Jul 2026

ACMG issues guidance for reporting uncertain genetic test variants

The American College of Medical Genetics and Genomics (ACMG) has published a new statement, Points to Consider for the Reporting of Variants of Uncertain Significance in Germline Genetic and Genomic Testing, providing guidance to laboratories and healthcare professionals on the reporting and communication of variants of uncertain significance (VUS) identified through genetic and genomic testing.

KFF poll finds vaccine myths reach many Americans but convince few

1

Jul 2026

KFF poll finds vaccine myths reach many Americans but convince few

KFF’s 2026 tracking poll found that many U.S. adults have heard common vaccine myths, including false claims about MMR, COVID-19, mRNA vaccines, and measles vaccines. Fewer adults strongly believe these myths, but a large, uncertain “malleable middle” remains, especially among those without a trusted health care provider, frequent social media users, some AI health-information users, and parents who delayed or skipped childhood vaccines.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.